Shingrix and Trelegy shield GSK from Advair falloutGlaxoSmithKline is expecting flat earnings this year, having earlier forecast a decline, as rising sales of new drugs Share XShingrix and Trelegy shield GSK from Advair fallouthttps://pharmaphorum.com/news/gsk-advair-shingles-vaccine-trelegy/
Trial could unlock asthma use for GSK’s TrelegyGlaxoSmithKline CEO Emma Walmsley has been predicting big things for respiratory triple therapy Trelegy in the next couple Share XTrial could unlock asthma use for GSK’s Trelegyhttps://pharmaphorum.com/news/trial-could-unlock-asthma-use-for-gsks-trelegy/
